



MEDIGARD LIMITED  
Suite 14, 30 Tedder Avenue, Main Beach QLD 4217 Australia  
Telephone +61 7 5528 5640  
E-mail: [office@medigard.com.au](mailto:office@medigard.com.au) [www.medigard.com.au](http://www.medigard.com.au)  
ABN 49 090 003 044

## ASX Announcement

Dear Medigard Shareholder

In May 2018 Medigard announced a commercial agreement with Bio-Link Australia Pty Ltd (Bio-Link) (<http://bio-link.com>) to assist Medigard with a new technology management and commercialisation program. The program has been established to identify, manage and commercialise new products to augment our existing syringe technology which is partnered with Sol-Millennium.

Our objective in this collaboration with Bio-Link is to seek new and worthwhile discovery or development projects that would build value over time with the intention that Medigard would own new patents and intellectual property and build a pipeline of medical technologies/products.

Over the past months we have reviewed many potential projects and with Bio-Link we have been assessing these projects against criteria established and supported by the Board of Medigard. My background assists in these activities and we have also sourced external expertise.

By the end of September 2018 we expect to have completed our assessment and arrived at a short list of the most promising and exciting projects.

Previously, I have been successful in translating such research into valuable commercial opportunities and products taken into clinical trials and partnerships, thus attracting investors to support the development programs.

We are pleased to be able to provide this update as the process has been very productive and the project evaluation phase is well advanced. Further information will be made available as it comes to hand.

Please feel free to contact me any time at [ian.dixon@medigard.com.au](mailto:ian.dixon@medigard.com.au).

Yours sincerely

Ian Dixon  
Executive Director  
13<sup>th</sup> September 2018